Germany-based Fresenius Medical Care, a provider of dialysis products and services, disclosed this week in a regulatory filing with the Securities and Exchange Commission that it is investigating potential violations of the Foreign Corrupt Practices Act.

The FCPA allegations concern “certain conduct in certain countries outside the United States and Germany,” the company stated in a Form 6-K. The company said it has voluntarily alerted the SEC and the Department of Justice.

The audit and corporate governance committee of the company's supervisory board, with the assistance of independent counsel, is conducting an internal review.

Fresenius Medical Care added that independent counsel and the compliance department have reviewed the company's anti-corruption compliance program, including internal controls related to compliance with international anti-bribery laws, “and appropriate enhancements are being implemented.”